Dry Eye Clinical Trials 2024

Dry Eye Clinical Trials 2024

Dry Eye research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in dry eye clinical trials today.

Dry Eye Clinical Trials

Here are the 6 most popular medical studies for dry eye

Popular filter options for dry eye trials

Dry Eye Syndrome Clinical Trials

View 36 Dry Eye Syndrome medical studies.

London, Ontario

Behavioural Intervention

SKY + ASTM + usual care for Depression

Recruiting1 award6 criteria
London, Ontario

People staring at computer screens for long hours, blinking less frequently, or having long-term contact lens wear are prone to dry eye disease (DED). DED is a multifactorial disease accompanied by inflammation of the ocular surface. Further, DED may degrade vision and is associated with depression and have an adverse impact on patient's quality of life. Sudarshan Kriya Yoga (SKY) incorporates standardized collection of breathing techniques followed by Automatic Self Transcending Meditation (ASTM) may help reduce stress, depression, and anxiety, enhance quality of life in patients diagnosed with DED. Thus, the investigators will be studying the effect of SKY plus ASTM on quality of life of DED patients. The investigators plan to conduct a single-center pilot RCT. Patients with DED will be randomized to SKY followed by ASTM plus Usual care (UC) or UC alone to assess changes in health-related quality of life (HRQOL). HRQOL is a vital construct focusing on impact of health on quality of life. Along with HRQOL the investigators will measure changes in extent of depression and anxiety. Additionally, majority of current ophthalmic literature describes changes in clinical variables whilst lacking information on HRQOL. Thus, there is a high necessity to assess if there is an association between HRQOL and routinely measured clinical data. Through this study the investigators shall attempt to correlate HRQOL with clinical data.

DES Clinical Trials

View 36 DES medical studies.

London, Ontario

Behavioural Intervention

SKY + ASTM + usual care for Depression

Recruiting1 award6 criteria
London, Ontario

People staring at computer screens for long hours, blinking less frequently, or having long-term contact lens wear are prone to dry eye disease (DED). DED is a multifactorial disease accompanied by inflammation of the ocular surface. Further, DED may degrade vision and is associated with depression and have an adverse impact on patient's quality of life. Sudarshan Kriya Yoga (SKY) incorporates standardized collection of breathing techniques followed by Automatic Self Transcending Meditation (ASTM) may help reduce stress, depression, and anxiety, enhance quality of life in patients diagnosed with DED. Thus, the investigators will be studying the effect of SKY plus ASTM on quality of life of DED patients. The investigators plan to conduct a single-center pilot RCT. Patients with DED will be randomized to SKY followed by ASTM plus Usual care (UC) or UC alone to assess changes in health-related quality of life (HRQOL). HRQOL is a vital construct focusing on impact of health on quality of life. Along with HRQOL the investigators will measure changes in extent of depression and anxiety. Additionally, majority of current ophthalmic literature describes changes in clinical variables whilst lacking information on HRQOL. Thus, there is a high necessity to assess if there is an association between HRQOL and routinely measured clinical data. Through this study the investigators shall attempt to correlate HRQOL with clinical data.

Phase 3 Dry Eye Clinical Trials

View 38 phase 3 dry eye medical studies.

Dry Eye Clinical Trials With No Placebo

View 38 dry eye medical studies that do not have a placebo group.

London, Ontario

Behavioural Intervention

SKY + ASTM + usual care for Depression

Recruiting1 award6 criteria
London, Ontario

People staring at computer screens for long hours, blinking less frequently, or having long-term contact lens wear are prone to dry eye disease (DED). DED is a multifactorial disease accompanied by inflammation of the ocular surface. Further, DED may degrade vision and is associated with depression and have an adverse impact on patient's quality of life. Sudarshan Kriya Yoga (SKY) incorporates standardized collection of breathing techniques followed by Automatic Self Transcending Meditation (ASTM) may help reduce stress, depression, and anxiety, enhance quality of life in patients diagnosed with DED. Thus, the investigators will be studying the effect of SKY plus ASTM on quality of life of DED patients. The investigators plan to conduct a single-center pilot RCT. Patients with DED will be randomized to SKY followed by ASTM plus Usual care (UC) or UC alone to assess changes in health-related quality of life (HRQOL). HRQOL is a vital construct focusing on impact of health on quality of life. Along with HRQOL the investigators will measure changes in extent of depression and anxiety. Additionally, majority of current ophthalmic literature describes changes in clinical variables whilst lacking information on HRQOL. Thus, there is a high necessity to assess if there is an association between HRQOL and routinely measured clinical data. Through this study the investigators shall attempt to correlate HRQOL with clinical data.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to dry eye

What are the top hospitals conducting dry eye research?

When it comes to cutting-edge research and clinical trials aimed at addressing the discomfort of dry eye, several leading hospitals are making significant strides. In Colorado Springs, the Vision Institute is actively involved in five ongoing dry eye trials and has a total track record of ten studies dedicated to this condition. Their first foray into dry eye research began in 2014, marking their commitment to finding innovative solutions. Meanwhile, the Eye Research Foundation in Newport Beach has four active dry eye trials underway and an impressive history of twenty-five previously conducted studies since embarking on its pioneering journey in 2014.

As we move to St. Louis, Ophthalmology Associates stands out with four currently active clinical trials focused on alleviating dry eye symptoms while having accomplished eighteen significant investigations since initiating their inaugural trial back in 2009. The dedication shown by these institutions towards understanding and treating this prevalent condition cannot be underestimated.

Additionally contributing to this important field is Oculus Research located in Garner—a relatively new entrant—currently conducting three active dry-eye trials; although they have only initiated four inquiries thus far (beginning as recently as2022), their impact holds enormous potential for future advancements within the realm of treating dry eyes effectively.

Last but certainly not least among our top hospitals is West Bay Eye Associates situated in Warwick which also boasts three current clinical investigations targeting various aspects related with relieving symptoms caused by chronic tear dysfunction; yet like Oculus Research , West Bay's findings continue shaping up through carrying out preliminary tests from merely two years ago(2019).

These exceptional hospitals collectively demonstrate an unwavering commitment to improving the lives of those affected by debilitating cases of chronic tears insufficiency.Through tireless efforts such as theirs,the horizon appears brighter for countless individuals seeking relief from chronically irritated or inflamed eyes that affect daily life comforts.These medical pioneers remind us how curiosity-driven exploration combined with advanced techniques can result into improved treatment options catering better quality-of-life options to dry eye sufferers worldwide.

Which are the best cities for dry eye clinical trials?

When it comes to dry eye clinical trials, several cities stand out as prime locations for cutting-edge research. Newport Beach, California leads the pack with 14 active trials focusing on treatments like Tivanisiran sodium ophthalmic solution, 5% Tavilermide ophthalmic solution, and K-161. Memphis, Tennessee follows closely behind with 9 ongoing studies examining interventions such as 5% Tavilermide ophthalmic solution and OTX-DED 0.3mg. Lastly, Kansas City in Missouri boasts 7 active trials exploring options like 5% Tavilermide ophthalmic solution and Tivanisiran sodium ophthalmic solution. These cities offer individuals suffering from dry eye access to advanced clinical trials that harbor potential breakthroughs in treatment strategies and improved quality of life.

Which are the top treatments for dry eye being explored in clinical trials?

Exciting advancements are underway in the search for effective treatments for dry eye. Among the top contenders being explored in clinical trials are:

  • Oxervate: Currently engaged in two active trials and has a total of two all-time dry eye trials since its debut in 2022.
  • Tivanisiran sodium ophthalmic solution: Making waves with its participation in two ongoing trials, it has accumulated a commendable count of two all-time dry eye studies since hitting the scene in 2021.
  • TearCare: Still proving its mettle, this treatment is currently involved in two active trials and has been part of five all-time dry eye studies since first being listed back in 2016.
  • IC265 Ophthalmic Solution 1%: A relative newcomer to the field, this solution is currently enlisted in one active trial while boasting one all-time dry eye study after making its debut just last year.

These promising options provide hope for individuals suffering from dry eyes as researchers continue their dedicated efforts to alleviate symptoms and enhance quality of life.

What are the most recent clinical trials for dry eye?

Exciting advancements are being made in the field of dry eye treatment, with a number of recent clinical trials offering hope to those affected by this condition. One promising trial focuses on the use of Omega-3 supplements, which have shown potential in alleviating dry eye symptoms. Additionally, a Phase 3 study has evaluated the effectiveness of 5% Tavilermide ophthalmic solution for managing dry eye. Another trial investigated OTX-DED 0.3mg as a potential treatment option during its Phase 2 stage. In addition, Low Dose OK-101 and TL-925 Arm both demonstrated promise for addressing dry eye symptoms during their respective Phase 2 studies. These developments bring us closer to improved therapies and relief for individuals experiencing the effects of dry eye.

What dry eye clinical trials were recently completed?

Several recent clinical trials have been completed, demonstrating the ongoing efforts to find effective treatments for dry eye. In September 2022, the State University of New york College of Optometry concluded a trial investigating Lifitegrast 5% Ophthalmic Solution. Similarly, in July 2022, Seikagaku Corporation completed their study on SI-614. Allgenesis Biotherapeutics Inc.'s trial for AG-80308 wrapped up in June 2022. These and other recently finished trials signify the commitment to addressing dry eye and provide hope for improved therapies in the future.